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ABSTRACT: Putrescine (1,4-diaminobutane) activates the autoprocessing and decarboxylation reactions of
human S-adenosylmethionine decarboxylase (AdoMetDC), a critical enzyme in the polyamine biosynthetic
pathway. In human AdoMetDC, putrescine binds in a buried pocket containing acidic residues Asp174,
Glu178, and Glu256. The pocket is away from the active site but near the dimer interface; however, a
series of hydrophilic residues connect the putrescine binding site and the active site. Mutation of these
acidic residues modulates the effects of putrescine. D174N, E178Q, and E256Q mutants were expressed
and dialyzed to remove putrescine and studied biochemically using X-ray crystallography, UV-CD
spectroscopy, analytical ultracentrifugation, and ITC binding studies. The results show that the binding
of putrescine to the wild type dimeric protein is cooperative. The D174N mutant does not bind putrescine,
and the E178Q and E256Q mutants bind putrescine weakly with no cooperativity. The crystal structure
of the mutants with and without putrescine and their complexes with S-adenosylmethionine methyl ester
were obtained. Binding of putrescine results in a reorganization of four aromatic residues (Phe285, Phe315,
Tyr318, and Phe320) and a conformational change in the loop 312-320. The loop shields putrescine
from the external solvent, enhancing its electrostatic and hydrogen bonding effects. The E256Q mutant
with putrescine added shows an alternate conformation of His243, Glu11, Lys80, and Ser229, the residues
that link the active site and the putrescine binding site, suggesting that putrescine activates the enzyme
through electrostatic effects and acts as a switch to correctly orient key catalytic residues.
S-Adenosylmethionine decarboxylase (AdoMetDC
1)i sa
critical enzyme in the polyamine biosynthetic pathway (1, 2)
and depends on a pyruvoyl group for the decarboxylation
reaction (3-5). It is synthesized as a proenzyme that
undergoes an apparent autocatalytic processing reaction to
generate the pyruvoyl group from an internal serine residue.
The enzyme converts S-adenosylmethionine (AdoMet) to
S-adenosyl-5′-(3-methylthiopropylamine) (dcAdoMet). The
propylamine group from the product is transferred to
putrescine to form spermidine or spermidine to form sper-
mine. Putrescine is generated by the decarboxylation of
ornithine by ornithine decarboxylase (ODC). Polyamine
levels are highly regulated in the cell and are closely linked
to normal cell growth and division. Both ODC and AdoMet-
DC are regulated through multiple mechanisms, catalyze
reactions in the earlier stages of polyamine biosynthesis, and
their reaction products are committed to polyamine biosyn-
thesis. Consequently, these enzymes are the focus of inhibitor
design, for both anticancer and antiparasitic agents (6, 7).
R-Diﬂuoromethylornithine is a suicide inhibitor of ODC and
is approved by the Food and Drug Administration for the
treatment of African sleeping sickness. Two inhibitors of
AdoMetDC, methylglyoxal bis(guanylhydrazone) and 4-ami-
dinoindan-1-one-2′-amidinohydrazone (CGP48664A), have
been the subject of several clinical trials (8-16). Although
neither compound is approved for clinical use, the polyamine
biosynthetic pathway remains an attractive target for both
cancer and antiparasitic chemotherapy.
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Published on Web 11/17/2008All AdoMetDCs currently characterized are pyruvoyl
enzymes, but they can be divided into two classes. Class
1 enzymes are present in bacteria and archaea, and class 2
enzymes are present in eukaryotes (5, 17). The human
AdoMetDC proenzyme contains 334 amino acid residues.
The processing reaction generates the R- (67 amino acids)
and  -subunits (266 amino acids) with the pyruvoyl group
at the N-terminus of the  -subunit (18). Only a small fraction
of the total AdoMet pool is in the decarboxylated form, and
AdoMetDC activity is very highly regulated according to
the need for polyamine synthesis (3, 19, 20). An important
part of this regulation in mammalian cells and some other
eukaryotes with class 2 AdoMetDCs, but not in plants, is
the activation of the enzyme by putrescine (3, 19-21).
Activation of the mammalian enzyme occurs at two stages:
the rate of processing of the proenzyme is stimulated, and
the decarboxylase activity is increased in the presence of
putrescine (22, 23). These factors provide a link between
the availability of putrescine and the production of
dcAdoMet, which is the other substrate of spermidine
synthase. This allows the very efﬁcient conversion of
putrescine into spermidine without increasing the steady state
pool of dcAdoMet. Mammalian cells therefore have sper-
midine content greatly in excess of putrescine, and c.1-2%
of the AdoMet is in the form of dcAdoMet (20, 24, 25).
AdoMetDCs from fungi and several protozoal parasites have
also been shown to be activated by putrescine (20, 22, 26, 27),
but this activation may occur only at the level of the
stimulation of activity (28, 29).
Structural studies of human AdoMetDC have indicated that
the functional form of human AdoMetDC is an (R )2 dimer
with one active site and one pyruvoyl cofactor per
protomer (23, 30, 31). The putrescine binding site is located
between two central  -sheets of the enzyme, away from the
active site and near the dimer interface (Figure 1A). One
end of putrescine is directly hydrogen bonded to Asp174,
Glu15, and Thr176. The other end is hydrogen bonded
through water molecules to Glu178, Glu15, Glu256, and
Ser113. The aliphatic chain of putrescine stacks against
Phe285 and Phe111 (Figure 1B). The putrescine molecule
is linked to the active site by several buried charged residues.
Mutations of residues in the putrescine binding site modulate
the effects of putrescine (32). Studies using site-directed
mutagenesis of the human and T. cruzi AdoMetDCs have
identiﬁed multiple residues whose alteration abolished the
activation (22, 29, 32-34). These include Asp174 in the
human enzyme, which is conserved in all of the known
putrescine-stimulated AdoMetDCs and is not present in other
class 2 AdoMetDCs such as those from plants, which are
not putrescine activated (33, 35).
MATERIALS AND METHODS
Apart from these studies, there is virtually no information
on the binding of putrescine to human AdoMetDC or the
changes brought about by this binding. To obtain further
insights into the mechanism of putrescine activation, we
undertook structural studies of human AdoMetDC and
putrescine binding mutants D174N, E178Q, and E256Q, with
FIGURE 1: Putrescine binding site of human AdoMetDC. (A) Ribbon diagram of AdoMetDC showing the putrescine binding site and the
active site with MeAdoMet bound (from pdb 1I7B). (B) Stereoview of interactions of putrescine with the enzyme. Putrescine carbon atoms
are colored green. Water molecules are shown as red spheres, and hydrogen bonds are shown as dashed lines.
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studied the biochemical properties of the putrescine free
enzymes using UV-CD spectroscopy, analytical ultracen-
trifugation, and isothermal titration calorimetry (ITC). The
crystal structures showed no global structural changes but
revealed a local rearrangement of four aromatic residues near
the putrescine binding site, Phe285, Phe315, Tyr318, and
Phe320, and a conformational change in the loop 312-320.
Biophysical studies conﬁrmed one putrescine binding site
per protomer and showed positive cooperativity between the
two binding sites within the dimer. Additionally, the D174N
mutant did not bind putrescine, and the E178Q and E256Q
mutants bind putrescine weakly with no cooperativity. Our
ﬁndings demonstrate that putrescine activates AdoMetDC
primarily through positioning of active site residues and
electrostatic effects relayed to the active site largely through
hydrogen bonding.
Cloning and Expression. The constructs for expression of
human AdoMetDC and mutants were modiﬁed from those
described previously (18, 32-34) to place the (His)6 tag at
the carboxyl end of the protein replacing the C-terminal
-QQQQQS sequence. Brieﬂy, primers 5′-d(ATTAAAGAG-
GAGAAATTAACTATGGAAGCTGCACATTT-TTTC)-
3′ with a Bser I site (underlined) and 5′-(GTGGTGGGAT-
TCACTCTGCTGTTG-TTGCTG)-3′ with a BamH I site
(underlined) were used as the sense and antisense primers
in a PCR reaction using pQE-SAMDC as a template. The
product was digested with Bser I and BamH1 and ligated
into plasmid pQE-C145S (36), which encodes the C-terminal
(His)6-tag, that had been digested with the same enzymes.
E. coli strain BL21(DE3) containing the AdoMetDC wild
type plasmid or plasmid for the mutant proteins was grown
at 30 °C overnight in a 2× YT media containing 100 µg/
mL ampicillin. The protein expression was induced by
addition of 1 mM isopropyl-1-thio- -D-galactopyranoside.
Cells were harvested after 4 h and resuspended in 50 mM
sodium phosphate at pH 8.0, 200 mM NaCl, 2.5 mM
putrescine, and 0.1 mM phenylmethylsulfonyl ﬂuoride. The
cells were lysed using a French pressure cell. The wild type
AdoMetDC and mutants were puriﬁed using a Ni-NTA
(Qiagen) afﬁnity column under native conditions in the
presence of 2.5 mM putrescine. Fractions containing the
desired protein were combined and concentrated by am-
monium sulfate precipitation (80%). The pellet was dissolved
and dialyzed against 50 mM phosphate, 200 mM NaCl, 1
mM ethylenediaminetetraacetic acid (EDTA), and 1 mM
tris(2-carboxyethyl)phosphine (TCEP) and loaded onto a
Sephacryl S-200 HR equilibrated in the same buffer and
connected to an AKTA (Pharmacia) chromatography system.
The eluted pure protein was concentrated by ammonium
sulfate precipitation (80%), dissolved, and dialyzed against
50 mM sodium phosphate pH 7.5, 1 mM TCEP, and 1 mM
EDTA. The concentrated protein was kept at -80 °C. The
puriﬁed protein correctly processed into a 31 kDa R subunit
and a 7.5 kDa   subunit as judged by SDS-PAGE
electrophoresis. The protein concentration was calculated
spectrophotometrically using the extinction coefﬁcient ε280
) 39,400 M-1 cm-1. Corrections for light scattering were
taken into account (37).
CD Spectroscopy. The CD experiments were performed
using a Jasco J-715 automatic recording spectrapolarimeter.
Spectra were recorded at 20 °C in10 mM phosphate at pH
7.5, 0.2 mM EDTA, and 0.2 mM TCEP in the absence and
presence of putrescine. Near-UV CD spectra were recorded
i na1c mrectangular quartz cell. The protein concentration
was 15 µM. The Far-UV CD spectra were recorded in a 1
mm cylindrical quartz cell. The protein concentration was
2.5 µM. The putrescine concentration was 4-fold higher than
the wild type or 40-fold higher than the variant proteins to
ensure that the proteins were saturated with putrescine. The
molar ellipticity, [Θ], was calculated as:
[Θ]) ∆Θ·Mw
10·l·c
(1)
where Mw is the mean molecular mass of amino acid residues
in AdoMetDC (115 Da), c is the protein concentration in
mg/mL, and l is the optical path length in centimeters.
Analytical Ultracentrifugation. Equilibrium sedimentation
experiments were performed using a Beckman XL-A ana-
lytical ultracentrifuge with an AN-60Ti rotor, operating at 4
°C. Samples were loaded into two-sector cells and spun at
three different speeds (12,000, 15,000, and 20,000 rpm). The
absorbance at 280 nm, A, was recorded as a function of the
radial position, r. Equilibrium was considered to be attained
when replicate scans separated by 6 h were indistinguishable.
The data sets for each protein were globally ﬁtted according
to a model in which single species are present in solution:
A)I+Ao·exp
(M·(r
2-ro
2))
(
2·R·T
(1-F·ν)·ω
2)
(2)
where I is the baseline offset constant, M is the molecular
weight of the species present in solution, ν is the partial
speciﬁc volume (0.749 cm3/g) calculated as described in ref
38, ω is the angular velocity, R is the gas constant in erg/
(mol·K), T is the temperature in Kelvin, and F is the density
of the solvent (1 g/cm3). The goodness of the ﬁt was assessed
by the quality of the residuals.
Isothermal Titration Calorimetry. The ITC experiments
were performed using a VP-ITC titration microcalorimeter
(MicroCal, Inc.). The procedure for these experiments has
been described previously (39). In brief, the experiments
were performed by injecting 3-10 µL of putrescine with
concentrations ranging between 0.7 and 16 mM into the
sample cell containing the protein solution. The protein
concentration varied between 12 and 87 µM, depending
on the magnitude of the heat effects observed. The buffer
used was 50 mM phosphate at pH 7.5, 1 mM EDTA, and
1 mM TCEP. Dilution effects were taken into account by
injecting the putrescine solution into the buffer. The heat
of the reaction after each injection, qi, was obtained by
integrating the peak after the injection using the ORIGIN
software provided by the manufacturer. The binding
isotherms were ﬁtted to a single set of sites (as described
previously (40)), model 1 in which 2 molecules of
putrescine bind to the dimeric protein according to Sch-
eme 1.
The heat of the reaction, Q, is deﬁned as follows:
Q)∆H·
A-√A
2-4·n·[L]T·[M]T
2·[M]T
where A)[M]T+n·[L]T+(1⁄K) (3)
13406 Biochemistry, Vol. 47, No. 50, 2008 Bale et al.where [M]T is the total protein concentration expressed per
monomer, [L]T is the total putrescine concentration, n is the
stoichiometry of the interaction, ∆H is the enthalpy of
binding, and K is the equilibrium constant.
Putrescine binding to wild type AdoMetDC was also ﬁtted
according to model 2 (Scheme 2) (41).
The heat of the reaction expressed per mol of protein
relates to the thermodynamic parameters as follows:
Q)
K1·[L]·∆H1+K1K2·[L]
2·(∆H1+∆H2)
(1+K1·[L]+K1·K2·[L]
2)
(4)
∆H1 and ∆H2 are the enthalpies of binding the ﬁrst and
second putrescine molecule, respectively. ∆H1 and ∆H2 are
both expressed per mol of monomer. K1 and K2 are the
apparent binding constants under the approximation that the
free putrescine concentration is equal to the total concentration.
The populations of each species in equilibrium were
calculated as follows:
[M2]
[MT]
) 1
(1+K1·[L]+K1·K2·[L]
2)
(5)
[M2L]
[MT]
)
K1·[L]
(1+K1·[L]+K1·K2·[L]
2)
(6)
[M2L2]
[MT]
)
K1·K2·[L]
2
(1+K1·[L]+K1·K2·[L]
2)
(7)
Fits to eqs 3 and 4 were done using nonlinear ﬁtting routine
NLREG (http://www.nlreg.com/), as described previously
(42).
Putrescine Analysis. Putrescine was released from bound
protein by treatment with perchloric acid and determined by
reverse-phase HPLC using postcolumn derivatization with
o-phthalaldehyde and ﬂuorescence detection (43).
Crystallization Conditions. The protein was buffer ex-
changed into 10 mM N-(2-hydroxyethyl)piperazine-N′-2-
ethanesulfonic acid, pH 7.5, 200 mM NaCl, and 1 mM
dithiothreitol (DTT) using Bio-Rad buffer exchange chro-
matography columns. For crystallization, the concentration
of the protein was maintained at 10 mg/mL for the
E178Q(-Put) mutant and at 5 mg/mL for the D174N(-Put)
and E256Q(-Put) mutants. The crystals were grown using
the hanging drop method at 22 °Ci n1 3 -16% polyethylene
glycol 8000, 100 mM tris(hydroxymethyl)aminomethane, pH
7.5-8.5, and 10 mM DTT. The crystals grew to a maximum
size of 0.2 mm × 0.15 mm × 0.1 mm in 2-3 days. For the
complexes of the mutants with MeAdoMet, each of the
mutants was incubated with 4-6 molar excess of MeAdoMet
for 24 h prior to crystallization. To obtain structures of the
mutants with putrescine bound, the E178Q and E256Q
mutant proteins were incubated with 4-6 molar excess of
putrescine for 2 h prior to crystallization.
Data Collection and Processing. The data for the
D174N(-Put), E178Q(-Put), and E256Q(-Put) were col-
lected at the A1 station of the Cornell High Energy
Synchrotron Source (CHESS) using a ADSC Quantum 210
detector. Data for D174N(-Put) and E256Q(-Put) were
collected over 180° with a 1° oscillation angle and 30 s
exposure time per image at a crystal to detector distance of
175 mm. Data for the E178Q(-Put) were collected over 110°
with a 1° oscillation angle and 60 s exposure time per image
at a crystal to detector distance of 185 mm. The data for the
putrescine free mutant complexes with MeAdoMet and
E178Q(+Put) and E256Q(+Put) were collected at NE-CAT
beamlines 24-ID-C and 24-ID-E, respectively, at the Ad-
vanced Photon Source (APS). Data were collected over a
range of 160°-360° w i t ha1sexposure time and a 1°
oscillation range. The crystal to detector distance varied
between200-280mm.ThedataforthewildtypeAdoMetDC-
(-Put) were collected at a home source using a Rigaku
R-Axis++ detector and Cu KR radiation from a Rigaku RU-
300 rotating anode generator. Data were collected over 140°
with a 0.5° oscillation angle and 20 min exposure per
oscillation with a crystal to detector distance of 180 mm.
The crystals were sequentially transferred to solutions with
2%, 5%, 8%, 15%, and 18% glycerol with 1-2 min
equilibration between each step. The crystals were ﬂash
frozen under liquid nitrogen for the MeAdoMet complexes
and putrescine bound mutants and the crystals were directly
ﬂash frozen under a liquid nitrogen stream for putrescine
free mutants and AdoMetDC(-Put). The data were indexed,
integrated, and scaled using the HKL2000 program suite (44).
The data collection statistics are summarized in Table 1.
Structure Determination and Reﬁnement. All of the
structures were determined by molecular replacement using
CNS (45). The structure of AdoMetDC(+Put)/MeAdo-
Met (PDB ID 1I7B), minus pyruvoyl group, putrescine,
MeAdoMet, and water molecules, was used as the search
model. The model building for the E178Q(-Put) structure
was done using the program O (46). The model building for
the rest of the structures was done using the program COOT
(47). The reﬁnement process included successive rounds of
simulated annealing, minimization, B-factor reﬁnement,
calculation of composite omit maps, difference Fourier maps,
and model building. After a few rounds of reﬁnement, the
improved difference Fo - Fc Fourier map was used to
identify ligands. The ligand was then added to the model
followed by another round of reﬁnement and picking of water
molecules. The parameter and the topology ﬁles for MeAdoM-
et were generated using the HIC-Up server (48). The
difference Fo - Fc Fourier map was also used to identify
conformational changes of residues in the putrescine binding
site as well as the active site. The ﬁnal reﬁnement statistics
are given in Table 2. A difference distance matrix program
was used to identify conformational changes in the backbone
of the protein structure (49, 50).
RESULTS
Studies were carried out with wild type AdoMetDC and
three mutants of the protein in which acidic residues that
hydrogen bond with putrescine (Figure 1B) were altered to
the corresponding amides. The proteins were dialyzed
extensively to remove bound putrescine. Direct analysis of
Scheme 1
Scheme 2
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<0.001 mol putrescine/mol protein.
Far-UV and Near-UV CD. Far-UV CD spectroscopy was
used to assess the effect of substitutions and putrescine
binding on the secondary structure of the protein. Figure 2A
shows the Far-UV CD spectra for the wild type AdoMetDC
mutants. In all cases, the spectra show a minimum at 218
nm and a maximum at 195 nm, typical of proteins with
signiﬁcant  -sheet content. The difference in ellipticity
among the proteins is within the experimental error indicating
that these single amino acid substitutions did not perturb the
secondary structure of AdoMetDC. Figure 2A inset shows
the effect of putrescine binding on the wild type AdoMetDC
secondary structure. It can be seen that the holo protein has
overall the same secondary structure as the apo form. The
small difference observed might be due to contributions of
the aromatic residues, which interact with putrescine (Phe111,
Phe285, Tyr318, Phe315, and Phe320) (23, 30, 31).
Near-UV CD is very sensitive to the environment of
aromatic side chains and therefore to the tertiary structure
of the protein. Figure 2B shows the near-UV CD spectra
for the AdoMetDC wild type and variant proteins. The
overall shapes of the spectra are similar with a minimum at
278 nm and a maximum at 256 nm. The small difference in
absolute values observed among proteins is probably due to
the slightly different orientation of the aromatic residues
caused by the substitutions. Putrescine has a small effect on
the near-UV CD for the wild type and E256Q proteins
(Figures 2C and D, respectively). Under saturated conditions
of putrescine, the ligand causes a small increase in ellipticity,
probably due to a more rigid environment of the aromatic
residues. However, no change in ellipticity was observed for
Table 1: Data Collection Statistics for AdoMetDC Mutants and Complexes
a
D174N
(-Put)
E256Q
(-Put)
E178Q
(-Put)
D174N (-Put)/
MeAdoMet
E256Q (-Put)/
MeAdoMet
E178Q (-Put)/
MeAdoMet
AdoMetDC
(-Put)
E178Q
(+Put)
E256Q
(+Put)
wavelength 0.9764 0.9764 0.9766 0.9795 0.9795 0.9795 1.5418 0.9792 0.9792
space group (Å) C2 C2 C2 C2 C2 C2 C2 C2 C2
a (Å) 90.60 90.71 90.57 99.22 94.44 100.15 90.57 91.60 92.35
b (Å) 55.24 55.90 56.26 50.60 50.08 51.07 55.54 54.49 53.54
c (Å) 74.22 74.33 74.05 68.82 70.17 68.95 74.31 74.58 74.71
  (°) 109.64 109.84 109.73 104.95 105.00 105.40 109.66 109.45 109.09
resolution (Å) 1.84 1.88 1.98 1.70 2.00 1.97 2.35 2.10 1.75
total reﬂections 88255 71106 53478 122776 54248 73956 41261 69216 123289
unique reﬂections 27642 27282 21433 35113 18180 23589 14524 19713 34072
redundancy 3.2(2.8) 2.6(2.3) 2.5(2.2) 3.5(2.5) 2.9(2.7) 3.1(2.5) 2.8(2.6) 3.5(2.8) 3.6(3.0)
% completeness 92.1(73.8) 96.7(87.0) 89.8(89.4) 96.3(78.0) 84.0(72.6) 98.6(91.1) 99.1(95.7) 96.8(79.8) 97.7(89.6)
I/σ 15.9(2.2) 16.0(2.0) 14.4(2.0) 15.4(2.2) 9.9(3.3) 15.0(3.4) 13.9(2.0) 34.4(6.2) 30.1(4.6)
Rsym
b 6.4(39.0) 4.9(39.6) 7.1(43.8) 8.3(32.8) 10.7(25.6) 8.0(23.8) 9.1(46.8) 3.7(12.2) 4.2(15.8)
Matthew’s coef. (Å3/Da) 2.28 2.31 2.32 2.18 2.09 2.22 2.30 2.29 2.28
solvent content (%) 45.1 45.9 45.9 42.5 40.1 43.5 45.5 45.3 45.0
a The values in parenthesis are for the highest resolution shell.
b Rsym>)ΣΣi|Ii - 〈I〉|/Σ〈I〉, where 〈I〉 is the mean intensity of the N reﬂections with
intensities Ii and common indices h,k,l.
Table 2: Reﬁnement Statistics for AdoMetDC Mutants and Complexes
D174N
(-Put)
E256Q
(-Put)
E178Q
(-Put)
D174N (-Put)/
MeAdoMet
E256Q (-Put)/
MeAdoMet
E178Q (-Put)/
MeAdoMet
AdoMetDC
(-Put)
E178Q
(+Put)
E256Q
(+Put)
resolution (Å) 1.84 1.88 1.98 1.70 2.00 1.97 2.35 2.10 1.75
R-factor
a 0.243 0.229 0.214 0.217 0.226 0.209 0.228 0.222 0.238
R-free
b 0.282 0.262 0.246 0.240 0.251 0.237 0.274 0.250 0.253
No of Non-H Atoms
protein 2411 2413 2411 2415 2412 2413 2443 2498 2500
ligand 8 8 12 28 28 28 8 14 6
water 179 148 103 163 186 206 103 138 194
B-Factors
protein (Å2) 46.4 46.1 37.7 31.0 35.4 29.5 50.1 40.4 31.8
ligand (Å2) 82.0 64.0 44.4(44.6) 32.8 40.1 44.0 84.9 71.2(39.7) 28.6
rms Deviations
bonds (Å) 0.007 0.008 0.006 0.010 0.022 0.014 0.007 0.010 0.016
angles 1.3 1.3 1.3 1.4 1.7 1.6 1.3 1.4 1.5
dihedrals 25.8 25.7 25.5 25.6 25.6 25.4 24.4 25.7 26.4
Ramachandran Plot
most favored
region (%)
90.0 90.4 93.1 91.6 90.3 91.2 86.6 91.2 89.7
additional favored
region (%)
8.9 8.8 6.2 6.9 9.3 7.7 11.9 8.1 10.3
generously allowed
region (%)
0.8 0.8 0.8 1.5 0.0 1.2 1.5 0.7 0.0
disallowed
region (%)
0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0
a R-factor ) Σhkl||Fobs| - k|Fcal||/Σhkl|Fobs|, where Fobs and Fcal are observed and calculated structure factors, respectively.
b In R-free, the sum is
extended over a subset of reﬂections (5%) that were excluded from all stages of reﬁnement.
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tively). This is expected for D174N as the substitution
abolishes putrescine binding to the protein (see later Results).
Analytical Ultracentrifugation of the AdoMetDC Proteins.
The X-ray structure of the human wild type AdoMetDC
shows that the protein crystallizes as a dimer (18, 23). To
assess if this is the functional unit in solution and if the
putrescine or mutations affect the oligomerization state of
the protein, sedimentation equilibrium experiments were
performed at three different speeds. For each protein, the
data were globally ﬁtted according to different oligomeric
models. In all cases, the experimental data were best ﬁtted
according to the single ideal species model (eq 2 in Materials
and Methods) and a molecular weight of a dimer. Figure 3
shows representative data for the wild type AdoMetDC. The
molecular weight obtained from the global ﬁt was 77.2 (
0.3 kDa in very good agreement with the theoretical one
(76.8 kDa). These results suggest that the monomers of
AdoMetDc interact with high afﬁnity. We estimated the
upper limit for the dimerization constant to be in the order
of 3 × 107 M-1.
Putrescine Binding to AdoMetDC Characterized by ITC.
In the ITC experiments, the heat released upon putrescine
binding to the proteins was measured. Figure 4A shows
representative heat effects for putrescine binding to wild type
AdoMetDC at 15 °C. The heat of binding is proportional to
the enthalpy and degree of binding and thus allows model
dependent estimates of the enthalpy (∆H), the binding
constant (K), and the stoichiometry (n). Figure 4B shows
the binding isotherm in which the heat effect is plotted as a
function of putrescine concentration. The experimental data
were ﬁtted according to eq 3 (in Materials and Methods),
which considers independent and noninteractive binding sites
(Scheme 1). The n parameter was kept constant as 1 molecule
of putrescine per monomer of wild type AdoMetDC. It can
be seen that the ﬁt to model 1 does not represent the
experimental data. The binding isotherm was then ﬁtted
according to eq 4 (in Materials and Methods), which
considers two interactive ligand binding sites per dimeric
protein, according to the model shown in Scheme 2. The
ﬁtted parameters are summarized in Table 3. We observed
that the second putrescine molecule binds with signiﬁcantly
higher afﬁnity to the dimeric protein than the ﬁrst one. We
found that K2 > K1/4, which implies that putrescine binding
to the wild type AdoMetDC protein has positive cooperat-
ivity. The cooperativity in a two-site system can be charac-
terized by
∆∆G)-R·T·ln(4·K2 / K1) (8)
We observe that ∆∆G is very signiﬁcant (Table 3) if we
compare it to the ∆G for the total process from the apo to
the holo forms. The ∆G for this process is calculated as
follows:
FIGURE 2: (A) Effect of mutations on the Far-UV CD spectra for
human wild type AdoMetDC (thick solid line), E256Q (thin solid
line), D174N (dashed line), and E178Q (dashed-and-dotted line).
Inset: Effect of putrescine on the Far-UV CD spectra; wild type
protein in the absence (thick solid line) and presence (thin solid
line) of putrescine. (B) Effect of mutations on the Near-UV CD
spectra for wild type AdoMetDC (thick solid line), E256Q (thin
solid line), D174N (dashed line), and E178Q (dashed-and-dotted
line). Effect of putrescine on the Near-UV CD spectra: wild type
AdoMetDC(C), E256Q (D), E178Q (E), and D174N (F) in the
absence (thick solid line) and presence (thin solid line) of putrescine.
FIGURE 3: Equilibrium sedimentation analysis of human AdoMetDC.
Representative traces for the wild type AdoMetDC at 12,000
(circles), 15,000 (squares), and 20,000 rpm (triangles). Solid lines
represent the global ﬁt according to eq 2. The molecular weight
obtained from the ﬁt was (77.2 ( 0.1) kDa.
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Figure 4C shows the changes in the population of the
different species in equilibrium as a function of the putrescine
concentration according to eqs 5, 6 and 7, in Materials and
Methods. We observe that the M2L concentration is never
higher than 20% of the total protein, and the high cooper-
ativity favors the binding of the second putrescine molecule
(M2L2). The stoichiometry of the interaction is consistent
with the crystal structure of the human AdoMetDC protein,
which shows that each monomer is able to bind one molecule
of putrescine (23, 30, 31).
Figure 5 shows the putrescine binding isotherms for the
AdoMetDC mutant proteins at 15 °C. One obvious conclu-
sion can be drawn from these results: the putrescine binding
to the D174N variant does not show any signiﬁcant heat
effect (Figure 5C), strongly suggesting that AdoMetDC-
D174N is no longer able to bind putrescine. To ensure that
the lack of heat effect was due to the lack of binding and
not to a very small enthalpy of binding at that temperature
or not enough protein concentration, experiments were
performed at different temperatures and different protein
concentrations (results not shown). In all cases, titration of
the D174N variant protein with putrescine produced no
signiﬁcant heat effect under our experimental conditions.
Thus, substitution of Asp174 by asparagine abolishes pu-
trescine binding all together.
However, the putrescine binding to the E256Q and E178Q
variant proteins shows signiﬁcant heat effects different from
that with wild type AdoMetDC. The isotherms for the E256Q
and E178Q can be ﬁtted according to eq 3 (model 1, Figures
5A and B). The ﬁtted parameters are summarized in Table
3. It is obvious from these results that the mechanisms of
putrescine interaction with the human AdoMetDC wild type
protein and the E256Q, E178Q, and D174N mutant proteins
FIGURE 4: Putrescine binding to wild type AdoMetDC by ITC. (A)
Representative isothermal titration calorimetry experiment at 15 °C.
Heat effects are recorded as a function of time during 45 successive
3 µL injections of 0.70 mM solution of putrescine into the cell
containing 0.0138 mM protein (a) or buffer (b). Buffer conditions
were 50 mM sodium phosphate at pH 7.5, 1 mM EDTA, and 1
mM TCEP. (B) Cumulative heat effect corresponding to the titration
in panel A (o) as a function of putrescine concentration. The thin
line is the ﬁt of the experimental data to eq 3. The thick line is the
ﬁt of the experimental data to eq 4 with the parameters listed in
Table 3. (C) Populations present in solution as a function of
putrescine concentration: [M2]/[MT] (thick solid line), [M2L]/[MT]
(dashed line), and [M2L2]/[MT] (thin solid line) calculated according
to eqs 5, 6 and 7, respectively.
Table 3: Thermodynamic Parameters for Putrescine Binding to the
AdoMetDC Proteins from the ITC Experiments at 15 °C
a
protein K1 K2 ∆H1 ∆H2 ∆G ∆∆G coop
AdoMetDC(-Put) 9 × 104 3.4 × 105 -5.8 1.2 -13.8
b -1.55
c
E256Q(-Put) 1.0 × 104 -6.1 -10.3
b NA
E178Q(-Put) 2.0 × 103 -1.2 -8.7
b NA
D174N(-Put) NE NE NE NA
a The binding constants are expressed in M-1, the enthalpies are
expressed in kcal per mol of monomer, and free energies are expressed
in kcal/mol. The error in the enthalpies and binding constants is ∼15%.
Note that for E256Q and E178Q, K1 ) K2 ) K and ∆H1 ) ∆H2. NA,
not applicable; NE, no heat effect was observed for D174N.
b Calculated
according to eq 9.
c Calculated according to eq 8.
FIGURE 5: Dependence of the heat effect of putrescine binding to
AdoMetDC-E256Q (A), AdoMetDC-E178Q (B), and AdoMetDC-
D174N (C) as a function of the ratio putrescine/protein. Solid lines
are the best ﬁt to eq 3 with the parameters in Table 3.
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glutamine not only abolishes the positive cooperativity for
the binding of the second molecule of putrescine to these
proteins but also dramatically decreases the putrescine
binding afﬁnity as compared to K1 for the wild type protein
(Table 3).
Crystal Structures of Putrescine Free AdoMetDC. Crystal
structures of AdoMetDC(-Put), D174N(-Put), E178Q(-Put),
and E256Q(-Put) were obtained. Difference Fourier maps
(Fo - Fc) and composite omit maps clearly show that
putrescine was absent in these structures. Instead, the
putrescine binding site in the AdoMetDC(-Put) and
D174N(-Put) and E256Q(-Put) mutants contains four
additional water molecules (Figure 6A). The nitrogen atom
of putrescine closer to the active site is replaced with a water
molecule (WA). This water molecule makes hydrogen bonds
to water molecules WB and WC, which in turn are hydrogen
bonded to Glu256 and Ser113, respectively. A fourth water
molecule (WD) is present roughly at the center of the
putrescine binding site and hydrogen bonds to WA. Asp174
is found in various conformations in the putrescine free
structures and is not hydrogen bonded to any conserved water
molecule. The structure of the E178Q(-Put) mutant shows
a ligand bound in the putrescine binding site. On the basis
of the electron density, which is triangular and ﬂat, a
molecule of urea was modeled into the putrescine binding
site. The carbonyl oxygen of urea occupies the same position
as the putrescine amino group closer to the active site and
WA and is hydrogen bonded to the enzyme through water
molecules. A stereoview of the ligand bound in the putrescine
binding site of the E178Q(-Put) mutant is shown in Figure
6B.
Three regions of the AdoMetDC show differences in the
putrescine free structures relative to the putrescine bound
structures: residues 171-173, 301-304, and 315-320
(Figure 7). In addition, the side chains of Phe285, Ser 312,
and Met314 show different conformation in the putrescine
FIGURE 6: Putrescine binding site in the putrescine free mutants. (A) Stereoview of putrescine binding site in the E256Q(-Put) mutant.
Water molecules are shown as red spheres, and hydrogen bonds are shown as dashed lines. (B) Stereoview of the putrescine binding site
in the E178Q(-Put) mutant. The density maps show a planar ligand comprising four atoms bound in the putrescine binding site. A molecule
of urea was modeled into the density. The difference Fo - Fc Fourier map is calculated omitting urea and is contoured at 4.0 σ. The
hydrogen bonds are omitted for clarity.
FIGURE 7: Dimeric form of AdoMetDC. Putrescine and MeAdoMet
bound in the active site are shown as sticks. There is no overall
change in the secondary structure. The loops undergoing confor-
mational change upon putrescine binding are colored red and
labeled.
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is required for putrescine binding. Four aromatic residues,
Phe285, Phe315, Tyr318, and Phe320, are repositioned in
the putrescine free structures mostly through changes in the
 1 torsion angles plus lateral shifts (Figure 8). The reposi-
tioning is associated with a 1.5 to 3 Å shift in loop 312-318
and causes the putrescine binding site to become more
solvent exposed. The biochemical relevance of loop 301-304
is unclear because it is far away from both the putrescine
binding site and the active site.
Crystal Structures of the Putrescine Free AdoMetDC/
MeAdoMet Complexes. Complexes of putrescine free mutants
with MeAdoMet were prepared to determine the effects of
the absence of putrescine on the conformation of the substrate
and active site residues. Difference Fourier maps showed
MeAdoMet bound in the active site of all three mutants
covalently linked to the pyruvoyl cofactor through a Schiff
base. The MeAdoMet conformation and the active site are
essentially the same as those for the complex of wt-
AdoMetDC with MeAdoMet (30). The 2′ and 3′ oxygen
atoms of the ribose each make a hydrogen bond to the
carboxylate group of Glu247. The adenine base stacks
between Phe7 and Phe223 with an overall syn conformation.
All three mutant complexes, including E178Q, showed the
same four conserved water molecules in the putrescine
binding site. The mutant complexes also showed the same
reorganization of the four aromatic residues Phe285, Phe315,
Tyr318, and Phe320 and the conformational change in loop
312-320 seen without putrescine and substrate analogue.
Structure of Mutants with Added Putrescine. Structures
of E178Q and E256Q were determined after the addition of
putrescine. The structure of D174N with putrescine was not
determined because biochemical studies reported here show
that this mutant does not bind putrescine. For both
E178Q(+Put) and E256Q(+Put) addition of putrescine
resulted in a reversal of the conformational changes in
Phe285, Phe315, Tyr318, and Phe320 and the 312-320 loop
seen in the putrescine free structures (Figure 8). The
putrescine molecule is in the same position as that observed
in all previously reported human AdoMetDC structures (23,
30, 31). In both structures, the aliphatic chain of putrescine
stacks against Phe111 and Phe285, with the latter residue
involved in repositioning the aromatic residues for the
putrescine free structures.
In the E256Q(+Put) mutant, one end of putrescine makes
direct hydrogen bonds to Glu15, Asp174, and Thr176, while
the other end makes water mediated hydrogen bonds to
Glu178 and Gln256 as previously observed (23, 30, 31). The
E178Q(+Put) mutant structure shows some interesting
differences. One end of the putrescine molecule makes direct
hydrogen bonds to Glu15, Asp174, and Thr176, and the other
end of the putrescine makes a water mediated hydrogen bond
with Glu256; however, there is no bridging water molecule
between putrescine and Gln178. Additionally, compared to
all other AdoMetDC structures, there is a conformational
change in residues Glu11, Lys80, Ser229, and His243 in
E256Q(+Put), which link the putrescine binding site and the
active site (Figure 9). The  1 torsion angle of His243, which
is important for both the processing and decarboxylation
reactions, changes from -63° to 90°. In the alternate
conformation, the side chain is pointed away from both the
pyruvyl cofactor and Ser229. Residues Lys80 and Glu11 also
undergo conformational changes and are hydrogen bonded
to each other through Ser254 and a water molecule. The other
FIGURE 8: Stereoview of the changes in the conformation of aromatic side chains occurring because of putrescine binding. AdoMetDC(+Put)
is shown in blue, and AdoMetDC(-Put) is shown in gray. The conformational shift in loop Phe320-Ser312 as an effect of the changes in
the aromatic side chains is clearly seen.
FIGURE 9: Stereoview of the comparison of the catalytic residues His243, Glu11, Lys80, and Ser229 in E256Q(+Put) and E256Q(-Put)
mutants. E256Q(+Put) has carbon atoms colored in green, and E256Q(-Put) has carbon atoms colored yellow.
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the disordered loop 291-299 into a short R-helix. This helix
is located at the dimer interface and interacts across the 2-fold
axis with the same helix from the other protomer. The closest
contact between the two helices is at the sulfur atoms of
Cys292, which are 3.6 Å apart.
DISCUSSION
Putrescine Binding to AdoMetDC and Mutants. Activation
of the AdoMetDC autoprocessing and decarboxylation reac-
tions is species dependent. The regulation of the polyamine
biosynthetic pathway by putrescine in certain species is
poorly understood and a thorough understanding of the
regulation of polyamine levels might provide an alternate
route for inhibiting the pathway. However, the activation of
autoprocessing and decarboxylation processes of human
AdoMetDC by putrescine and other diamines is well-known
and studied (23). The rate of activation of the enzyme is
highest by putrescine when compared to other diamines. The
only previous direct measurements of putrescine binding to
AdoMetDC were carried out with the T. cruzi enzyme (29).
The Kd, which was determined by ultraﬁltration and by
ﬂuorescence change measurements, was 150-180 µM. This
is more than an order of magnitude greater than the values
measured here by ITC for the human enzyme, but, as
described below, it has been shown recently that a much
more active enzyme that is not putrescine-activated is formed
by a heterodimer between T. cruzi AdoMetDC and a
structurally homologous regulatory protein (51). Although
Asp174 appears to be a key residue in binding for both
enzymes since mutation to valine in T. cruzi (29)o r
asparagine in human (Table 3) abolished binding, it appears
that there is little similarity in the activation of the parasite
and mammalian enzymes. Our value is much closer to that
which would be expected on the basis of the amount of
putrescine needed for enzyme activation (Ka of c. 20
µM) (3, 19-21) or processing (Ka c. 50 µM) (23). The latter
value may be increased because of competition for binding
by nucleic acids in the reticulocyte lysates used for studying
processing in coupled transcription/translation systems.
The tight binding of putrescine to human AdoMetDC is
also consistent with the difﬁculty in removing putrescine
from the enzyme. This requires extensive dialysis, and it is
noteworthy that all of the previously published structures of
the protein contain a bound putrescine even though it was
not added to the buffers used for crystallization. The current
results using ITC conﬁrm that there is only one putrescine
binding site in the human AdoMetDC R  protomer and rules
out postulated models in which two putrescine molecules
bring about the changes in AdoMetDC activity (19, 34, 52).
The previously unrecognized cooperative binding of pu-
trescine to mammalian AdoMetDC is likely to explain the
complex kinetics for activation previously reported (52).
Furthermore, the ITC data conﬁrm that in solution, the
putrescine molecule binds in the site identiﬁed by the crystal
structure. Mutation of Asp174 totally abolished binding,
while mutations of Glu178 and Glu256 greatly reduced the
afﬁnity for putrescine. Potato AdoMetDC, which is not
activated by putrescine, is generally quite similar to the
human structure but is an R  monomer (35). In this structure,
several amino acid substitutions in the putrescine binding
pocket (Asp174 to valine, Phe111 to arginine, Leu13 to
arginine, and Phe285 to histidine) introduce side chains that
mimic the role of putrescine in the human enzyme. Thus,
dimerization and putrescine activation may be linked.
Structure of the Putrescine Binding Site with and without
Putrescine. Previous structural studies clearly identiﬁed
the putrescine binding site in human AdoMetDC (23, 30, 31).
Putrescine is bound between the two central  -sheets of the
enzyme at a distance of 15 to 20 Å from the active site. The
putrescine amino group farther from the active site is directly
hydrogen bonded to Asp174, Glu15, and Thr176. The closer
amino group is hydrogen bonded through water molecules
to Glu178, Glu15, Glu256, and Ser113. The carbon chain
of putrescine stacks against Phe285 and Phe111. The crystal
structure also shows that there is only one molecule of
putrescine bound per monomer.
Previously reported structures provided insights into the
mechanism of putrescine activation of human AdoMetDC
(23). On the basis of these studies, the mechanism of
putrescine activation was believed to be due to two reasons.
First, putrescine binds inside the  -sandwich region through
charge neutralization of acidic residues and hydrophobic
interactions to aromatic residues, and it was proposed that
stability of the  -sandwich is necessary for the correct
orientation of residues for the autoprocessing reaction.
Second, there is a hydrogen bonding network from the
putrescine binding site to His243, which plays a critical role
in the autoprocessing mechanism and in the decarboxylation
processes though electrostatics and hydrogen bonding (23, 33).
The crystal structures of the putrescine free enzyme and
mutants provide newer insights into the putrescine binding
site. The putrescine binding site is solvent accessible from
one side and in the absence of putrescine the site is ﬁlled
with water molecules. The comparison of crystal structures
of putrescine free and putrescine bound AdoMetDC struc-
tures showed no signiﬁcant changes in the secondary
structure. The Far-UV CD experiments have also shown that
there is no signiﬁcant change in the secondary structure of
AdoMetDC and the mutants upon putrescine binding, sup-
porting the crystal structures. These observations suggest that
putrescine has little effect in stabilizing the secondary
structure of the enzyme as previously thought.
Conformational Changes upon Putrescine Binding. Dif-
ference distance matrix analysis (49, 50) showed signiﬁcant
changes in the CR positions of residues 171-173, 301-304,
and 312-320. Asp174 is required for putrescine binding,
and residues 171-173 are near the entrance of the putrescine
binding site. Consequently, these residues appear to serve
as a gate to the putrescine binding site. In addition,
repositioning of the aromatic residues Phe285, Phe315,
Tyr318, and Phe320 and the loop containing residues
312-320 further opens the putrescine binding site (Figure
8). Binding of putrescine displaces two water molecules, and
Phe285 moves toward the aliphatic portion of the putrescine
molecule, followed by closing off of the entrance thus
shielding the putrescine from the solvent. These changes
result in closer contacts between the protein side chains and
an enhancement of electrostatic effects. The near-UV CD
experiments showed a small effect for the wt-AdoMetDC
and the E256Q mutant, which is due to the change in the
aromatic side chain positions. This ﬁnding is in agreement
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Tyr318, and Phe320 observed upon putrescine binding.
PositiVe CooperatiVity of Putrescine Binding. Human
AdoMetDC is a homodimer with two active sites and two
putrescine binding sites. ITC studies showed positive coop-
erativity of putrescine binding for WT-AdoMetDC while no
cooperativity was observed for the mutants (Table 4). Loop
312-320, which undergoes a shift upon putrescine binding,
is at the dimer interface (Figure 10A). The main contacts
between this loop and the 2-fold related protomer occur
between the residues Ser312-Ser312′, Met314-Cys310′,
Phe315-Arg307′, and Gln311-Gln311′, where the prime
designates residues in the 2-fold related protomer. The effect
of putrescine binding and conformational changes in the loop
Table 4: Effects of Putrescine on AdoMetDC and Mutants
putrecine
binding
a
processing
b
(-Put)
processing
c
(+Put)
decarboxyl-
ation
d (-Put)
decarboxyl-
ation
e (+Put)
cooperativity
in Put binding
f
WT yes 1 5-8 1 4 yes
D174N no 1 ND 1 ND ND
E178Q yes 1 1 4 1 none
E256Q yes 1 1 1 1 none
a As determined by ITC.
b Relative rate of processing in the absence of putrescine.
c Relative increase in processing with putrescine added measured
at 1 mM Put (23).
d Relative rate of decarboxylation in the absence of putrescine.
e Relative rate of decarboxylation with putrescine added measured at
0.2 mM Put (32).
f Cooperativity between active sites as determined by ITC.
FIGURE 10: (A) Dimer interface of AdoMetDC. The monomers are colored green and gray, respectively. The loop 315-320 is colored red
in one monomer and blue in the other. The residues at the interface are shown in sticks. (B) Charge network between the putrescine binding
site and the active site. Putrescine, MeAdoMet, and the active site pyruvoyl group carbon atoms are colored green. Water molecules are
shown as red spheres, and hydrogen bonds are shown as dashed lines.
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putrescine binding site are relayed through the dimer interface
to the putrescine binding site in the other monomer. Not
consistent with this argument is that the E178Q and E256Q
mutants bind putrescine but do not show cooperativity even
though the same conformational changes are observed upon
putrescine binding for loop 312-320 and the four aromatic
residues, suggesting that other factors are involved.
Structural Insights into Putrescine Stimulation of AdoMet-
DC ActiVity. Structural comparisons suggest no global
conformational changes upon putrescine binding to AdoMet-
DC; however, several local conformational changes are
observed. This suggests that the primary effect of putrescine
is electrostatic and that this effect is transmitted to the active
site though hydrogen bonding (Figure 10B). Binding of
putrescine introduces two positive charges into a binding
pocket that contains three conserved acidic residues. Glu178
and Glu256 are hydrogen bonded through water to the
putrescine amino group closer to the active site and are near
Lys80, which is disordered in most AdoMetDC structures.
Lys80 is also near Glu11 and His243, two residues important
for both autoprocessing and catalysis. Through this network,
the pKa of His243 would increase in the presence of
putrescine and decrease in its absence. The side chain of
Glu11 is positioned to assist in protonation/deprotonation
of the His243. Glu11 is an essential residue for the activation
by putrescine, although it plays no direct role in putrescine
binding. Mutation of Glu11 to glutamine abolishes putrescine
activation of processing (34), and mutation to aspartate causes
putrescine to be an inhibitor of processing (23). Mutation
E11K prevents processing completely (34). Mutation E11Q
greatly reduces AdoMetDC activity (34) and reduces the
stimulation by putrescine by 60%. The E11D change reduces
activity of the processed enzyme by about 4-fold and
putrescine activation by about 50% (unpublished work). The
mutant K80A has only about 10% activity and is stimulated
by putrescine only at very high concentrations with a Ka of
400 µM. Similarly, the processing of this mutant is much
slower than wild type and is putrescine activated but requires
much higher levels of putrescine (Ka of c. 1 mM). Combina-
tion of the K80A/E11D mutation abolishes the inhibitory
effect on processing of this mutation and the K80A and
K80A/E11D mutants have identical responses to putrescine
(unpublished work).
ITC binding results show that the D174N mutant protein
does not bind putrescine. The E178Q and E256Q mutants
bind putrescine but show no stimulation of processing. The
negative charge appears to be key for inﬂuencing active site
electrostatics, and its absence blocks the effects of putrescine.
In contrast, the E178Q mutant has decarboxylation activity
in the absence of putrescine comparable to wild type with
putrescine, while the decarboxylation activity of the E256Q
mutant is not simulated by putrescine. These results are
consistent with a proposed model of charge relay through
Lys80 to Glu11 to His243 resulting from putrescine binding.
Another possibility is that putrescine utilizes electrostatic
interactions to correctly position active site residues. Evi-
dence for a structural switch comes from the structure of
the E256Q(+Put), which shows conformational changes in
Glu11, Lys80, Ser229, and His243. The largest change occurs
in His243, which rotates about its  1 torsion angle by about
150°. In this conformation, the side chain is pointed away
from both the pyruvoyl cofactor and Ser229. Previous
biochemical data show that the catalytic activity of the
E256Q(-Put) mutant is far lower than the wild type enzyme
and is not stimulated by the addition of putrescine (32),
suggesting this positioning of residues represents a low
activity state in which putrescine is unable to inﬂuence the
correct positioning of active site residues. The structure
E178Q(+Put) lacks a bridging water molecule between
putrescine and Gln178, resulting in no activation of the
E178Q(-Put) mutant by putrescine.
Implications for Other AdoMetDCs. The effect of pu-
trescine varies among species. Class 1a and 1b enzymes have
a fold that is similar to both the N-terminal and C-terminal
halves of the class 2 protomer; however, class 1 AdoMetDCs
do not have a putrescine binding site and are not stimulated
by putrescine. Class 2a AdoMetDCs include the plant
enzymes and have a fold very similar to that of the class 1a
protomer but are monomeric rather than dimeric (35). The
class 2a enzymes contain a buried cluster of charged residues
that is reminiscent of the putrescine binding site found in
human AdoMetDC; however, the pocket is ﬁlled by two
arginine residues that are not present in any class 2b enzyme.
Class 2a AdoMetDCs are not stimulated by putrescine but
have constitutive processing and decarboxylation activities
similar to those of the putrescine activated human AdoMetDC.
Multiple sequence alignments show that all of the key
active site residues are conserved in the class 2a and class
2b AdoMetDCs as are the residues that connect the buried
charged cluster. Class 2a and 2b are distinguished in part
by the nature of the buried cluster. Within class 2b, there
are two subclasses. The ﬁrst is represented by human
AdoMetDC and is distinguished by a conserved Lys80.
Within this group, the three acidic residues in the putrescine
binding site are conserved. The four aromatic residues are
not entirely conserved; however, these residues are always
aromatic or large hydrophobic residues. The second subclass
includes apicomplexan parasites and is distinguished by the
substitution of isoleucine in place of Lys80. A hydrophobic
residue would interrupt the electrostatic transfer of charge
and suggests that putrescine stimulates this group of AdoMet-
DCs by a different mechanism than that of human AdoMet-
DC. Studies on the Trypanosome brucei AdoMetDC showed
that putrescine stimulates the decarboxylation reaction;
however, the activity was about 1000-fold lower than the
activity of the human AdoMetDC (51). Recently, Phillips
and co-workers showed that formation of a heterodimer
between AdoMetDC and a structurally homologous but
inactive regulatory protein resulted in decarboxylation rates
comparable to that of human AdoMetDC (51). Furthermore,
the heterodimeric T. brucei AdoMetDC was not stimulated
by the addition of putrescine. No structures are available for
this group of AdoMetDCs, and the mechanism of stimulation
remains to be determined.
Regulating polyamine levels by controlling the enzymes
in the polyamine biosynthetic pathway is a promising target
for cancer and antiparasitic therapy (6, 7). Our results suggest
that an alternate approach to inhibiting AdoMetDC would
be to target the putrescine binding site. Compounds binding
to this site that mimic the effects of some of the mutants
described above may prevent processing or signiﬁcantly
block activity.
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